Insmed Incorporated (NASDAQ:INSM) CFO Sells $67,925.52 in Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 1,066 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.72, for a total value of $67,925.52. Following the transaction, the chief financial officer now owns 118,863 shares of the company’s stock, valued at $7,573,950.36. This represents a 0.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Sara Bonstein also recently made the following trade(s):

• On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00.

Insmed Price Performance

NASDAQ:INSM traded down $0.47 during trading hours on Friday, reaching $65.25. 3,087,759 shares of the company’s stock were exchanged, compared to its average volume of 1,881,810. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a market capitalization of $11.67 billion, a P/E ratio of -11.76 and a beta of 1.12. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The business’s 50-day simple moving average is $71.29 and its two-hundred day simple moving average is $72.44.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. The company’s quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the previous year, the company earned ($1.10) earnings per share. Sell-side analysts expect that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on INSM. JPMorgan Chase & Co. boosted their target price on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. Bank of America increased their price objective on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. Finally, Truist Financial reissued a “buy” rating and issued a $105.00 price target (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $83.67.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CIBC Asset Management Inc lifted its holdings in shares of Insmed by 3.5% in the third quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 149 shares in the last quarter. Commerce Bank raised its position in Insmed by 2.4% during the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 163 shares during the period. GAMMA Investing LLC lifted its stake in Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares in the last quarter. Atomi Financial Group Inc. boosted its position in Insmed by 1.4% during the 3rd quarter. Atomi Financial Group Inc. now owns 23,248 shares of the biopharmaceutical company’s stock worth $1,697,000 after acquiring an additional 314 shares during the period. Finally, V Square Quantitative Management LLC purchased a new position in Insmed during the 3rd quarter valued at about $30,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.